【英文】M13B指导原则(草案)

本指导原则旨在为在已证明至少一种规格的体内生物等效性(BE)的申请中,获得一种或多种其他规格制剂的 BE 研究豁免提供建议。

文书类别:药品/文件依据/技术指导 文书页数:29页 更新时间:2025-04-23

应用地区:全国 应用岗位:药品注册专员 法规依据:《药品注册管理办法》

¥ 0.00
占位
INTERNATIONAL CO UNCIL FOR HARMONISATION OF TECHNICAL REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED GUIDELINE BIOEQUIVALENCE FOR IMMEDIATE - RELEASE SOLID ORAL DOSAGE FORMS A DDITIONAL STRENGTHS B IOWAIVER M13 B Draft version Endorsed on 13 March 2025 Currently under public consultation At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.

展开

在线咨询
回到顶部